Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Expert Rev Pharmacoecon Outcomes Res ; 22(6): 913-918, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35400272

ABSTRACT

INTRODUCTION: Drug reimbursement decisions that spark public controversy are potential signals that processes used to reach such decisions do not adequately reflect society's goals. Such controversial decisions appear to be a characteristic of Quality-Adjusted Life Year (QALY)-based Incremental Cost Effectiveness Ratio (ICER)-dominated decision-making systems. QALY-based ICER-heavy systems have several known weaknesses that lead to individual and societal preferences being either ignored or considered in an unsystematic and inconsistent manner. AREAS COVERED: We reprise some of the key inadequacies of QALY-based ICER analyses and suggest that there are other means including multicriteria decision analysis (MCDA) and cost-benefit analysis based on willingness to pay (WTP) measures by which to partially mitigate these weaknesses. EXPERT OPINION: For long, the inadequacies of QALY-based ICER-heavy decision-making systems have been rationalized with the answer: 'while the method is a second best, it is the best we currently have.' In light of the equally well-developed and widely utilized alternatives available, this resistance to improve assessment processes should not be accepted by policy makers. Health technology assessment bodies should consider and, with appropriate modifications, adopt these alternatives as they have the potential to result in more comprehensive, systematic, and accountable decision-making.


Subject(s)
Policy , Technology Assessment, Biomedical , Cost-Benefit Analysis , Humans , Quality-Adjusted Life Years
2.
Int J Health Policy Manag ; 8(7): 424-443, 2019 07 01.
Article in English | MEDLINE | ID: mdl-31441279

ABSTRACT

BACKGROUND: The accountability for reasonableness (A4R) framework defines 4 conditions for legitimate healthcare coverage decision processes: Relevance, Publicity, Appeals, and Enforcement. The aim of this study was to reflect on how the diverse features of decision-making processes can be aligned with A4R conditions to guide decision-making towards legitimacy. Rare disease and regenerative therapies (RDRTs) pose special decision-making challenges and offer therefore a useful case study. METHODS: Features operationalizing each A4R condition as well as three different approaches to address these features (cost-per-QALY-focused and multicriteria-based) were defined and organized into a matrix. Seven experts explored these features during a panel run under the Chatham House Rule and provided general and RDRT-specific recommendations. Responses were analyzed to identify converging and diverging recommendations. RESULTS: Regarding Relevance, recommendations included supporting deliberation, stakeholder participation and grounding coverage decision criteria in normative and societal objectives. Thirteen of 17 proposed decision criteria were recommended by a majority of panelists. The usefulness of universal cost-effectiveness thresholds to inform allocative efficiency was challenged, particularly in the RDRT context. RDRTs raise specific issues that need to be considered; however, rarity should be viewed in relation to other aspects, such as disease severity and budget impact. Regarding Publicity, panelists recommended transparency about the values underlying a decision and value judgements used in selecting evidence. For Appeals, recommendations included a life-cycle approach with clear provisions for re-evaluations. For Enforcement, external quality reviews of decisions were recommended. CONCLUSION: Moving coverage decision-making processes towards enhanced legitimacy in general and in the RDRT context involves designing and refining approaches to support participation and deliberation, enhancing transparency, and allowing explicit consideration of multiple decision criteria that reflect normative and societal objectives.


Subject(s)
Decision Making , Insurance Coverage , Insurance, Health , Rare Diseases , Regenerative Medicine
3.
BMJ ; 335(7615): 318, 2007 Aug 18.
Article in English | MEDLINE | ID: mdl-17703014
6.
Healthc Pap ; 3(1): 83-5; discussion 87-94, 2002.
Article in English | MEDLINE | ID: mdl-12811116

ABSTRACT

Laupacis, Anderson and O'Brien propose amending regulations to get better information so that effective drugs can be made available without bankrupting the healthcare system. We reckon that this proposal is rather like shutting the barn door after the horse has bolted. If you want to avoid bankruptcy, first you have to know what you can afford to spend. From our observations as a public agency responsible for setting drug subsidies in New Zealand, operating within a budget constraint may better help to achieve many of the desired outcomes.


Subject(s)
Budgets/organization & administration , Drug and Narcotic Control/economics , National Health Programs/economics , Canada , Cost Control , Cost-Benefit Analysis , Drug Costs/statistics & numerical data , Evidence-Based Medicine , Health Services Accessibility/economics , Humans , New Zealand
SELECTION OF CITATIONS
SEARCH DETAIL
...